Brittany Alloway, DO
General Practice · Eugene, ORNPI 1386037240
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 172 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 13.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $981, 9.0 times the $109 reported in 2020. Among general practice clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 172 payments — averaging $19.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$430
- AbbVie$428
- Lilly USA, LLC$275
- Novo Nordisk$258
- Amgen$255
- GSK$252
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,26199%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 28 | $430 |
| AbbVie | 22 | $428 |
| Lilly USA, LLC | 13 | $275 |
| Novo Nordisk | 18 | $258 |
| Amgen | 13 | $255 |
| GSK | 13 | $252 |
| Exact Sciences | 8 | $211 |
| Novartis | 6 | $131 |
| Boehringer Ingelheim | 6 | $129 |
| Boston Scientific | 6 | $126 |
| Bayer | 4 | $80 |
| Sanofi Pasteur Inc. | 4 | $79 |
| AstraZeneca | 4 | $78 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $73 |
| Johnson & Johnson | 3 | $54 |
| Aimmune Therapeutics, Inc. | 2 | $53 |
| Sanofi-aventis U.S. LLC | 2 | $42 |
| Mylan Specialty L.p. | 2 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Axsome Therapeutics, Inc. | 2 | $37 |
| Amarin Pharma, Inc. | 2 | $35 |
| Edwards Lifesciences | 1 | $32 |
| Madrigal Pharmaceuticals | 1 | $29 |
| Viiv Healthcare Company | 1 | $25 |
| Exeltis, USA Inc. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Gilead | 1 | $16 |
| Nestle Healthcare Nutrition Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$3,293 in reported general payments places this provider in the 95th percentile of 1,274 general practice providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 95 | $83,354 |
| OzempicSemaglutide | 19 | $23,775 |
| Arnuity ElliptaFluticasone Furoate | 14 | $6,047 |
| Atorvastatin Calcium | 324 | $3,473 |
| Levothyroxine Sodium | 273 | $3,472 |
| Bupropion XlBupropion Hcl | 100 | $3,401 |
| Duloxetine Hcl | 52 | $3,072 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 12 | $3,045 |
| Estradiol | 71 | $2,910 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $2,341 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 47 | $1,859 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 60 | $1,800 |
| Rosuvastatin Calcium | 106 | $1,688 |
| Gabapentin | 104 | $1,591 |
| Irbesartan | 80 | $1,389 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $430 | $83,35495 claims |
| Novo NordiskOzempic | $258 | $23,77519 claims |
| GSKArnuity Ellipta | $252 | $6,04714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,274 general practice providers in Oregon.
Other general practice in Eugene
- Thomas HoustonEugene$6K
- Shawn EckstromEugene$5K
- Hyungsup LeeBeaverton$36K
- Darin O'BryanCoos Bay$34K
- Matthew McLaughlinSpringfield$27K
- Timothy BealsTigard$24K
- Bruce MitchellMedford$21K
- Marlene CoveyBend$13K
- Aaron TinkleCanby$12K
- Nathan DoyelSherwood$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.